【SUNZEN 0148 交流专区】宏诚生科

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("THE COMPANY" OR "SUNZEN") -        ACQUISITION OF SHARES IN EYE NATION MEDICAL SDN. BHD.
Further to the Company’s announcement on 6 May 2024, the Board of Directors of Sunzen (“Board”) wishes to announce that the Company, had on 1 October 2024 entered into a Share Sale Agreement (“SSA”) with Mr. Lee Peng Hwa (“Lee”) and Madam Lay Lee Chin (“Lay”) (collectively referred to as “the Vendors”), for the acquisition of seventy thousand (70,000) ordinary shares (“Sale Shares”), representing seventy percent (70%) of the equity interest of Eye Nation Medical Sdn. Bhd. [Registration No. 200301031140 (633561-V)] (“ENMSB”) for a total cash consideration of Ringgit Malaysia Six Million Three Hundred and Seventy Thousand (RM6,370,000.00) only (“Purchase Price”) (“the Acquisition”) in accordance with the terms and conditions of the SSA. Please refer to the attachment for details of the announcement. This announcement is dated 1 October 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3488216

Attachments Sunzen_Ann_Acq of Shares_Eye Nation_FINAL.pdf

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN GROUP BERHAD ("THE COMPANY" OR "SUNZEN") (FORMERLY KNOWN AS SUNZEN BIOTECH BERHAD)SALE AND PURCHASE OF SHARES AGREEMENT WITH PURE NUTRITIONAL PRODUCTS SDN. BHD. IN RESPECT OF - (1)        DISPOSAL OF 2,000,000 ORDINARY SHARES IN SUNZEN CORPORATION SDN. BHD.(2)        DISPOSAL OF 500,000 ORDINARY SHARES IN SUNZEN LIFESCIENCES SDN. BHD.(“DISPOSAL OF SHARES”)
The Company had on 18 February 2025 entered into a Sale and Purchase of Shares Agreement (“Agreement”) with Pure Nutritional Products Sdn. Bhd. [Registration No. 199801003406 (45932-H)] (“Pure Nutritional” or “Purchaser”) for disposal of 100% of the equity interest in its wholly-owned subsidiaries namely Sunzen Corporation Sdn. Bhd. [Registration No. 199801014339 (470468-W)] (“SCSB”) and Sunzen Lifesciences Sdn. Bhd. [Registration No. 200701000077 (758075-D)] (“SLSB”) (collectively known as “Target Companies”), which operates in the animal health businesses, for a total cash consideration of Ringgit Malaysia Seventeen Million Three Hundred Thousand (RM17,300,000.00) only (“Consideration”) (“Disposal of Shares”). Please refer to the attachement for details of the announcement. This announcement is dated 18 February 2025.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3524231

Attachments Sunzen_SPA_Pure Nutritional Products.pdf

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN GROUP BERHAD ("THE COMPANY" OR "SUNZEN") (FORMERLY KNOWN AS SUNZEN BIOTECH BERHAD)SALE AND PURCHASE OF SHARES AGREEMENT WITH PURE NUTRITIONAL PRODUCTS SDN. BHD. IN RESPECT OF - (1)DISPOSAL OF 2,000,000 ORDINARY SHARES IN SUNZEN CORPORATION SDN. BHD.(2)DISPOSAL OF 500,000 ORDINARY SHARES IN SUNZEN LIFESCIENCES SDN. BHD.("DISPOSAL OF SHARES")
Unless otherwise defined herein, all terms and acronyms used herein shall be the same as those defined in the Company’s announcement dated 18 February 2025. Further to Sunzen’s announcement dated 18 February 2025 in relation to the Sale and Purchase of Shares Agreement with Pure Nutritional Products Sdn. Bhd. in respect of the Disposal of Shares. The Board of Directors of Sunzen wishes to announce the following additional information:- 1. Particular of any liabilities, including contingent liabilities, in relation to the Proposed Disposal which remain with Sunzen, together with the details and justification for such arrangements. Sunzen remain responsible for contingent liability under SCSB arising from the legal case that initiated against SCSB by the claimant. However, SCSB should not be held liable for occupier liability and vicarious liability as claimed and has applied for striking out for the case, of which is pending the decision by the Court. 2. Quantify the liability of the Target Companies which will remain with Sunzen. In the event the Court decides otherwise, SCSB would be liable for a claim of RM6,500.00 as well as the general damages which shall be decided and assessed by the Court accordingly. The general damages could not be quantified at the current state. However, based on the Company's legal advisor and internal assessment, the general damages are unlikely to have any material impact on Sunzen, if the Court ruled in favour of the claimant. 3. Any guarantee given to the Target Companies. There was no guarantee given by Sunzen to the Target Companies. 4. Directors’ and substantial shareholders’ shareholding of the Purchaser. The Directors of Pure Nutritional and their respective shareholding in Pure Nutritional are as follows:- Name Shareholding Direct Indirect Diong Sing Peng 1 (0.01%) Nil Diong Siew Gi 15,001 (99.99%) Nil Diong Swee Hoon Nil Nil

Pure Nutritional is a private limited company under the Companies Act 2016. Substantial shareholder is not applicable to Pure Nutritional in accordance with Section 134 of the Companies Act 2016.

This announcement is dated 20 February 2025.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2024	31 Dec 2023	31 Dec 2024	31 Dec 2023
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	27,346	0	50,310	0
2	Profit/(loss) before tax	2,893	0	3,753	0
3	Profit/(loss) for the period	2,034	0	2,285	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,942	0	2,424	0
5	Basic earnings/(loss) per share (Subunit)	0.27	0.00	0.33	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.1900		0.2000